ArticleIndian journal of surgical oncology2021
Estimation of Serum MicroRNA 21 as a Tumour Marker in Carcinoma Oesophagus.
Article in Indian journal of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Serum MicroRNA 21 and Tumour Marker in Oesophagus Cancer: Correspondence.Indian journal of surgical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, carcinoma of the oesophagus is the sixth leading reason for deaths due to malignancy. MicroRNAs (MiRs) are a cluster of small non-coding RNAs that have potent stability in stored RNA samples. This strengthens their potential as biomarkers. This study aimed to isolate MiR 21 from serum samples of carcinoma oesophagus patients and healthy subjects for determining its strength of association in various stages of the carcinoma oesophagus. This is a case-control study with 1:1 matched cases and controls. We included 40 patients of carcinoma oesophagus and 40 healthy individuals. Serum separated from venous blood samples of cases and controls was stored at - 80 °C. Total RNA was extracted, and the real-time polymerase chain reaction was used to measure the serum MiR 21. On statistical comparison, we found a marked increase in MiR 21 in cases of carcinoma oesophagus when compared with the controls (p < 0.0001). This study also showed a steady rise in the MiR 21 levels with the disease severity (p < 0.0001). Based on the result of this study, we conclude that MiR 21 levels can be used as a novel marker for assessing disease severity in carcinoma oesophagus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.